Skip to main
GKOS
GKOS logo

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos (GKOS) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 38%
Hold 0%
Sell 8%
Strong Sell 0%

Bulls say

Glaukos Corp has demonstrated positive momentum in its revenue performance, particularly with glaucoma products, as evidenced by a 45% increase in glaucoma revenue to $110 million in 3Q25, surpassing consensus estimates. The company's operational efficiency is reflected in an improved operating margin of (7.0%), significantly better than the previous year's (8.1%) margin and consensus expectations. Additionally, the Corneal Health segment has showcased robust growth with a CAGR of approximately 15.2% globally since 2020, indicating strong market positioning and future potential for products like Epioxa, as adoption rates are anticipated to rise significantly in the coming years.

Bears say

Glaukos Corp faces a negative outlook primarily due to lower-than-expected market growth for minimally invasive glaucoma surgeries (MIGS) and the anticipated slow uptake of its novel products, such as iDose TR and the iStent infinite. Additionally, the company's sales have demonstrated vulnerability, with a reported 4.7% decline in legacy surgical glaucoma revenues, alongside concerns of declining Corneal Health revenues driven by the transition to Epioxa. The company also faces risks related to potential changes in the reimbursement landscape and increased competition, which could hinder future revenue growth and market share.

Glaukos (GKOS) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Glaukos (GKOS) Forecast

Analysts have given Glaukos (GKOS) a Buy based on their latest research and market trends.

According to 13 analysts, Glaukos (GKOS) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $123.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $123.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Glaukos (GKOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.